ArticleFrontiers in oncology2026

A real-world comparison study of the efficacy of dual-target first-line rescue treatment of human epidermal growth factor receptor 2 positive advanced breast cancer: trastuzumab combined with pertuzumab versus trastuzumab combined with pyrotinib.

Liang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.